According to a report by Intel Market Research, the global Gene Therapy On Cardiovascular Disease Market was valued at USD 292 million in 2025 and is estimated to reach USD 526 million in 2026, before growing to USD 58.5 billion by 2034, representing an 80.2% CAGR during 2026–2034. The market covers cardiovascular-focused gene transfer, gene augmentation, gene editing and selected gene-silencing platforms designed to alter gene expression or address disease-driving molecular biology.
Explore the full report: https://www.intelmarketresearch.com/gene-therapy-on-cardiovascular-disease-market-market-11659
Why Is Demand Increasing?
- Large cardiovascular disease burden: WHO estimates that cardiovascular diseases caused 19.8 million deaths in 2022, representing 32% of global deaths. The scale of the disease burden creates a long-term rationale for therapies targeting underlying molecular mechanisms.
- Expanding human proof-of-concept: Clinical programs are now generating human data across non-ischemic heart failure, hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, Danon disease and Friedreich ataxia cardiomyopathy.
- Advances in genetic-medicine platforms: AAV-based gene replacement, non-viral delivery, lipid nanoparticles and in-vivo gene-editing approaches are expanding the technology landscape, while developers continue working on cardiac delivery efficiency, durability and safety.
Cardiovascular Gene-Therapy & Clinical Development Watch
The cardiovascular gene-therapy landscape is moving from a predominantly preclinical field toward a broader clinical development ecosystem. AAV-mediated gene replacement remains among the most clinically advanced approaches, with programs targeting genetically defined cardiomyopathies and acquired heart failure. At the same time, non-viral delivery and gene-editing technologies are being developed to address limitations associated with AAV cargo capacity, pre-existing immunity and potential re-dosing.
Recent clinical developments are expanding the number of cardiovascular indications producing human data. Tenaya Therapeutics has reported interim data for TN-201 in MYBPC3-associated hypertrophic cardiomyopathy and TN-401 in PKP2-associated arrhythmogenic cardiomyopathy, while AskBio’s AB-1002 has progressed into Phase 2 development for non-ischemic cardiomyopathy and HFrEF.
Segmentation Highlights
- By Type: Viral Gene Therapy and Non-Viral Gene Therapy. The underlying report identifies Non-Viral Gene Therapy as the leading category, while AAV-based viral vectors account for many of the most clinically advanced cardiac gene-replacement programs.
- By Application: Heart Disease, Vascular Disease and Other Applications. Vascular Disease is identified as the leading application in the underlying report.
- By End User: Hospitals, Specialty Clinics, and Academic & Research Institutes. Hospitals represent the principal administration setting because cardiovascular gene therapy requires advanced cardiac infrastructure and multidisciplinary care.
- By Therapeutic Approach: Gene Augmentation, Gene Silencing and Gene Editing. Gene augmentation is described as the most clinically mature cardiovascular gene-therapy strategy.
- By Target Indication: Ischemic Conditions, Heart Failure, Arrhythmias, Inherited Cardiomyopathies and Other Cardiovascular Conditions.
Regional Outlook
- North America: The leading development region, supported by U.S. biotechnology companies, specialist clinical centers, advanced-therapy manufacturing capabilities, financing and FDA interaction.
- United States: Multiple developers are reporting human cardiovascular gene-therapy data, including programs targeting HCM, Danon disease, arrhythmogenic cardiomyopathy and heart failure.
- Europe: Strong academic cardiology networks, rare-disease cohorts and advanced-therapy regulatory infrastructure support clinical development.
- Asia-Pacific: Combines a large cardiovascular disease population with expanding genomic-medicine capabilities. Japan, China, South Korea and Australia have established academic and regulatory ecosystems.
- Latin America: Represents an earlier-stage access market where participation is more likely to concentrate around multinational trials and specialized centers.
- Middle East & Africa: Adoption is heterogeneous, with Gulf healthcare systems and selected academic centers offering stronger infrastructure for genomic medicine and advanced therapies.
Download the free sample report: https://www.intelmarketresearch.com/download-free-sample/11659/gene-therapy-on-cardiovascular-disease-market-market
Why This Market Matters
Cardiovascular gene therapy represents an emerging approach aimed at addressing disease-driving molecular mechanisms rather than relying solely on downstream symptom management. The market is developing across inherited cardiomyopathies, heart failure, arrhythmogenic disease, lipid disorders and vascular indications.
The commercial opportunity is closely linked to clinical validation. Rare genetically defined cardiomyopathies provide focused patient populations and clear molecular targets, while broader heart-failure and vascular applications could provide larger addressable populations if developers demonstrate sufficient safety, durable benefit and scalable delivery.
Competitive Landscape
- Biogen — Included among the major companies profiled in the cardiovascular gene-therapy market.
- Novartis — Included among the leading large biopharma companies profiled in the report.
- Gilead Sciences — Participates in the broader genetic-medicine competitive landscape covered by the study.
- Sarepta Therapeutics — Included among the key gene-therapy companies profiled by the report.
- Alnylam Pharmaceuticals — Included among the major genetic-medicine companies analyzed in the competitive landscape.
View the full report: https://www.intelmarketresearch.com/gene-therapy-on-cardiovascular-disease-market-market-11659
FAQ
Q: What is the Gene Therapy On Cardiovascular Disease Market size and forecast?
A: The market was valued at USD 292 million in 2025, is estimated at USD 526 million in 2026 and is projected to reach USD 58.5 billion by 2034 at an 80.2% CAGR during 2026–2034.
Q: Which region leads the cardiovascular gene-therapy market?
A: North America is identified as the leading development region, with the United States concentrating biotechnology companies, clinical centers, manufacturing expertise, financing and FDA interaction.
Q: Which therapeutic approaches are covered by the market?
A: The report covers gene augmentation, gene silencing and gene editing. Gene augmentation is described as the most clinically mature cardiovascular gene-therapy strategy.
What Does the Full Report Cover?
The full study provides a detailed assessment of the cardiovascular gene-therapy market across delivery type, application, end user, therapeutic approach, target indication and geography. It includes market sizing for the 2025 base year, the 2026 estimate and the 2026–2034 forecast period. The report examines viral and non-viral approaches, heart and vascular applications, hospitals, specialty clinics and academic institutions, alongside gene augmentation, silencing and editing strategies. Regional and country-level analysis covers North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. The study also evaluates competitive intelligence, clinical programs, delivery technologies, manufacturing constraints, regulatory developments, market access, reimbursement considerations and commercialization readiness.
View the complete report: https://www.intelmarketresearch.com/gene-therapy-on-cardiovascular-disease-market-market-11659
Download the free sample: https://www.intelmarketresearch.com/download-free-sample/11659/gene-therapy-on-cardiovascular-disease-market-market
About Intel Market Research
Intel Market Research provides quantified market research and strategic intelligence across emerging industries and technology-driven markets. Its research covers market sizing, forecasting, segmentation, regional analysis, competitive intelligence and industry dynamics. The company states that its reports combine primary research with structured secondary research and data triangulation.
Contact Details
Website: www.intelmarketresearch.com
Asia-Pacific: +91 9169164321
